loader
Please Wait
Applying Filters...

Minakem Generic APIs Minakem Generic APIs

X

Technical details about Paxalisib, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
1. Also known as: 1382979-44-3, Paxalisib, Gdc0084, Paxalisib [usan], 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine, Chembl3813842
Molecular Formula
C18H22N8O2
Molecular Weight
382.4  g/mol
InChI Key
LGWACEZVCMBSKW-UHFFFAOYSA-N
FDA UNII
P5DKZ70636

Paxalisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine
2.1.2 InChI
InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
2.1.3 InChI Key
LGWACEZVCMBSKW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C
2.2 Other Identifiers
2.2.1 UNII
P5DKZ70636
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-pyrimidinamine, 5-(8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-(1,4)oxazino(4,3-e)purin-2-yl)-

2. 5-(6,6-dimethyl-4-(4-morpholinyl)-8,9-dihydro-6h-(1,4)oxazino(4,3-e)purin-2-yl)-2-pyrimidinamine

2.3.2 Depositor-Supplied Synonyms

1. 1382979-44-3

2. Paxalisib

3. Gdc0084

4. Paxalisib [usan]

5. 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine

6. Chembl3813842

7. P5dkz70636

8. Gdc 0084

9. G02441729

10. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[4,3-e]purin-2-yl)pyrimidin-2-amine

11. G-02441729

12. 2-pyrimidinamine, 5-(8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-(1,4)oxazino(4,3-e)purin-2-yl)-

13. 2-pyrimidinamine, 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-[1,4]oxazino[4,3-e]purin-2-yl]-

14. 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6h-[1,4]oxazino[4,3-e]purin-2-yl]-2-pyrimidinamine

15. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-(1,4)oxazino(3,4-e)purin-2-yl)pyrimidin-2-amine

16. 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6h-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine

17. Paxalisib [inn]

18. Paxalisib (usan/inn)

19. Unii-p5dkz70636

20. Schembl10239943

21. Gtpl10097

22. Bcp18386

23. Ex-a1019

24. Gdc-0084rg7666

25. Bdbm50177662

26. Mfcd30187522

27. Nsc792987

28. Rg7666

29. S8163

30. Who 11102

31. Akos030526470

32. Zinc149645112

33. Ccg-268430

34. Cs-5638

35. Db15186

36. Nsc-792987

37. Rg-7666

38. Sb19742

39. Compound 16 [pmid: 27096040]

40. Ac-31529

41. Bs-15481

42. Hy-19962

43. D11869

44. A909398

45. 5-(6,6-dimethyl-4-(4-morpholinyl)-8,9-dihydro-6h-(1,4)oxazino(4,3-e)purin-2-yl)-2-pyrimidinamine

2.4 Create Date
2012-07-23
3 Chemical and Physical Properties
Molecular Weight 382.4 g/mol
Molecular Formula C18H22N8O2
XLogP3-0.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count2
Exact Mass382.18657197 g/mol
Monoisotopic Mass382.18657197 g/mol
Topological Polar Surface Area117 Ų
Heavy Atom Count28
Formal Charge0
Complexity552
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


Post Enquiry
POST ENQUIRY